Expanded access policy

Âé¶¹ÆÆ½â°æ is developing vonafexor for patients with Alport syndrome through clinical trials, which we believe are the most appropriate and fastest way to make it available to patients.
At this time, Âé¶¹ÆÆ½â°æ does not offer expanded access (also known as ‘compassionate use’) to vonafexor outside of its clinical trials. Patients who complete an Âé¶¹ÆÆ½â°æ clinical trial may be offered continued treatment under a continuation protocol. We will review the expanded access policy as vonafexor development progresses.

Requests for information: please send an email to clinicaltrial@enyopharma.com. We will acknowledge receipt within 10 business days.
For Trials information: .

Last updated: 18th November 2026